Search Results
Your search for Blood matches 4856 pages
Showing 1 - 50Plasma miR-371a-3p Predicts Recurrence in Stage I Testicular Cancer: Interim Results From the CLIMATE Study
In the management of stage I testicular cancer, a persistent clinical dilemma is the identification of patients who truly need adjuvant treatment after orchiectomy rather than active surveillance alone. Interim results from the CLIMATE study found post-orchiectomy plasma miR-371a-3p (miR-371), a...
‘Promising’ Signal Only: ctDNA in Early Breast Cancer Not Yet Ready for Clinical Use
Despite compelling prognostic associations across multiple retrospective data sets, no interventional trial has demonstrated that acting on circulating tumor DNA testing results in early breast cancer improves patient outcomes. Clinicians should therefore proceed with caution until such evidence...
COA and Flatiron Health Study Finds Patients May Experience Longer Survival in Community Oncology Settings
Patients diagnosed with metastatic breast cancer and non–small cell lung cancer (NSCLC) had longer survival compared to national benchmarks when treated in independent community oncology practices, according to a new study commissioned by the Community Oncology Alliance (COA) and conducted by...
Four-Drug Regimen Induces High Complete Response Rate in Early-Stage Classical Hodgkin Lymphoma
High objective response and complete response rates were observed with treatment with brentuximab vedotin and nivolumab in combination with doxorubicin and dacarbazine chemotherapy in patients with early-stage classical Hodgkin lymphoma, according to the results of a phase II trial published in...
FDA Approves Vepdegestrant for ER-Positive, HER2-Negative, ESR1-Mutated Advanced Breast Cancer
On May 1, the U.S. Food and Drug Administration (FDA) approved vepdegestrant (Veppanu), a heterobifunctional protein degrader, for the treatment of adult patients with estrogen receptor (ER)-positive, HER2-negative, ESR1-mutated advanced or metastatic breast cancer, as detected by an FDA-authorized ...
Can PFAS Exposure Raise ALL Risk?
Early exposure to per- and polyfluoroalkyl substances (PFAS), a group of widely used compounds known as “forever chemicals,” may be associated with a higher risk of developing acute lymphoblastic leukemia (ALL), according to findings published by Vieira et al in the Journal of Exposure Science...
Belzutifan/Lenvatinib Outperforms Cabozantinib After Checkpoint Inhibitors in Advanced Renal Cell Carcinoma
At the first and second interim analyses of the phase III LITESPARK-011 trial, treatment with the novel first-in-class hypoxia-inducible factor-2 alpha (HIF-2α) inhibitor belzutifan plus lenvatinib improved progression-free survival, produced a higher objective response rate, and showed a trend...
AI-Powered, Next-Generation Sequencing Blood-Based Assay Evaluated for Detection of Post-HCT Relapse in AML and MDS
Monitoring for relapse with an artificial intelligence (AI)-powered peripheral blood-based tool called AlloHeme demonstrated greater sensitivity in predicting relapse after hematopoietic cell transplantation (HCT) in patients with acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) than ...
RAS Inhibitor Daraxonrasib in Metastatic Pancreatic Cancer
The treatment landscape for advanced pancreatic cancer is shifting. The common RAS mutation is now targetable and the race for the most effective inhibitor is heating up. In mid-April, Revolution Medicines announced positive results from its phase III RASolute 302 clinical trial of daraxonrasib, an ...
Cancer Researcher Awarded Sjöberg Prize For Describing Tumors’ Evolution
This year’s Sjöberg Prize of $1 million U.S. dollars was awarded to a British cancer researcher who has provided fundamental knowledge about evolution in tumors. Professor Charles Swanton, FRCP, BSc, PhD, at the Francis Crick Institute in London, described how tumors’ mutations arise and develop....
Exposure to Wildfire Smoke May Be Linked to Increased Risk of Developing Several Types of Cancer
Exposure to wildfire smoke was associated with a significantly increased risk of lung, colorectal, breast, bladder, and blood cancers, according to results from a study presented at the American Association for Cancer Research (AACR) Annual Meeting 2026 (Abstract 6252). Although it’s known that...
High-Risk Smoldering Multiple Myeloma: BCMA-Directed CAR T-Cell Therapy Shows Activity
A single infusion of the chimeric antigen receptor (CAR) T-cell therapy ciltacabtagene autoleucel led to a 100% measurable residual disease (MRD)-negativity rate in patients with high-risk smoldering multiple myeloma, according to results from CAR-PRISM, a phase II clinical trial, presented at the...
ASH/ISTH Create Guidelines for Pediatric VTE Prophylaxis
The American Society of Hematology (ASH) and the International Society on Thrombosis and Haemostasis (ISTH) have released a set of comprehensive clinical practice guidelines for the use of anticoagulant prophylaxis in pediatric patients at risk of venous thromboembolism. The guidelines were...
Electroacupuncture May Relieve Cognitive, Psychological Symptoms in Breast Cancer Survivors in Pilot Study
Electroacupuncture may alleviate some persistent neuropsychiatric symptoms experienced by breast cancer survivors, including psychological distress and cognitive impairment, according to the results of a randomized, double-blinded pilot trial published in the Journal of the National Cancer...
American Cancer Society Announces New Pediatric, Adolescent, and Young Adult Cancer Journal
The American Cancer Society (ACS) has announced the launch of its fourth medical journal, Pediatric, Adolescent & Young Adult Cancer. This international, multidisciplinary publication will feature peer-reviewed original research and solicited content on the latest advances in cancers affecting...
Researchers Identify Blood-Based Biomarker for Cancer Risk in People With Lynch Syndrome
Researchers at The University of Texas MD Anderson Cancer Center have discovered a new blood-based biomarker that can help identify and characterize asymptomatic people with Lynch syndrome who are more susceptible to developing cancer based on early immune detection signatures, allowing clinicians...
Ulrich Steidl, MD, PhD, Named Director of Montefiore Einstein Comprehensive Cancer Center
International leader in blood cancer and stem cell research Ulrich Steidl, MD, PhD, has been named Director of the Montefiore Einstein Comprehensive Cancer Center (MECCC) and Vice President of Cancer Medicine at Montefiore Einstein. He has acted as Interim Director of MECCC, which is a National...
New ASH HematOmics Program Offers Blood Cancer Data Integration Tool to Accelerate Research
In collaboration with St. Jude Children's Research Hospital and the Munich Leukemia Laboratory, the American Society for Hematology has introduced the ASH HematOmics Program (ASHOP), which may be one of the most comprehensive collections of blood cancer data ever to accelerate discovery, according...
Japanese Study Looks at Rates of Cancer Therapy–Related AML
Some therapies used to treat cancer may increase the risk of later developing secondary hematologic malignancies. A population-based study in Japan has revealed a gradual increase in the rates of therapy-related acute myeloid leukemia (tAML) in recent years—especially after breast cancer treatment. ...
Presence of ctDNA at the End of Neoadjuvant Therapy May Predict Breast Cancer Recurrence
Fragments of tumor DNA circulating in the bloodstream of patients with breast cancer may predict whether they are likely to experience relapse—especially when samples are taken after the patients have received treatments prior to surgery. Findings presented at the 15th European Breast Cancer...
Agent Orange Exposure Linked to MDS Risk and Progression
In a recent study published in Blood Advances, Sekeres et al examined whether exposure to Agent Orange, a dioxin-contaminated herbicide used during the Vietnam War, is associated with the development and clinical characteristics of myelodysplastic syndromes (MDS). Given the established links...
Machine-Learning Model for HCC Risk Prediction May Outperform Current Methods
An interpretable machine-learning framework, called PRE-Screen-HCC, may predict risk levels for developing hepatocellular carcinoma (HCC) more accurately than publicly available risk scores, according to findings from a large population-based multicentric study published in Cancer Discovery. “Our...
Dynamic, Accessible Risk Stratification Tool Created for Smoldering Multiple Myeloma
Researchers have developed a dynamic risk stratification tool for patients with smoldering multiple myeloma to predict their chance of progression to active multiple myeloma. The tool, called Precursor Asymptomatic Neoplasms by Group Effort Analysis–Smoldering Multiple Myeloma (PANGEA-SMM),...
AI Use in Cancer Diagnosis, Prognosis, and Treatment: Are We There Yet?
The promise of artificial intelligence (AI) technologies to provide highly personalized oncology care for patients and improve outcomes has been decades in the making. In a 1987 editorial in The New England Journal of Medicine, pioneering nephrologist and health economist William B. Schwartz, MD,...
Neoadjuvant GOLP in High-Risk Intrahepatic Cholangiocarcinoma
In an interim analysis of a Chinese phase II/III trial (ZSAB) reported in The New England Journal of Medicine, Shi et al found that a neoadjuvant GOLP regimen (gemcitabine plus oxaliplatin, lenvatinib, and a PD-1 inhibitor [toripalimab]) improved event-free survival vs no neoadjuvant treatment in...
ASH 2025: Myelofibrosis Roundup
For myelofibrosis, the treatment landscape is poised for change as new targets have emerged, and treatments are evolving beyond the standard Janus kinase (JAK) inhibitors. Novel therapies are being paired with the commonly used JAK inhibitor ruxolitinib, as reflected by a wealth of studies...
In Celebration of a Decades-Long Journey of Discovery and Innovation
On October 1, 2025, Benjamin L. Ebert, MD, PhD, celebrated the 1-year anniversary of being named President and Chief Executive Officer (CEO) of Dana-Farber Cancer Institute in Boston. He also holds the titles of Director of Dana-Farber/Harvard Cancer Center, the Richard and Susan Smith Professor of ...
POEMS Syndrome: Diagnostic Clues From Neuropathy to Bone Marrow Findings
POEMS syndrome is a poorly understood and complex paraneoplastic plasma cell disorder characterized by peripheral neuropathy and multisystem involvement, including organomegaly, endocrinopathy, monoclonal plasma cell dyscrasia, and skin changes. Clinical manifestations are thought to result from...
A Decade of Research Leads to New Guidance on Using Colony-Stimulating Factors in Anticancer Treatment
ASCO has published an updated guideline describing the latest evidence on using hematopoietic colony-stimulating factor (CSF) to support anticancer treatment, namely chemotherapy and stem cell transplantation.1 “We wanted to update these guidelines both to include the newer evidence as well as...
Myelofibrosis: Treatment Landscape Is Poised for Change
For myelofibrosis, the treatment landscape is poised for change as new targets have emerged, and treatments are evolving beyond the standard Janus kinase (JAK) inhibitors. Novel therapies are being paired with the commonly used JAK inhibitor ruxolitinib, as reflected by a wealth of studies...
Study Finds Inferior Survival Among Black Patients With AML, Independent of Cytogenetic Risk
Among patients with acute myeloid leukemia (AML) who were treated with intensive chemotherapy on clinical trials from the ECOG-ACRIN Cancer Research Group (ECOG-ACRIN), Black race was found to be an independent predictor of inferior survival, with outcomes not being explained by cytogenetic risk....
Small Phase II Study Examines Triplet Regimen for Patients With HER2-Positive Breast Cancer and Leptomeningeal Metastasis
Patients with leptomeningeal metastasis have historically had few treatment options. Now, researchers have found a combination of the tyrosine kinase inhibitor tucatinib and the monoclonal antibody trastuzumab, plus the chemotherapy capecitabine, may improve symptoms and extend survival in some...
SMFM Issues New Clinical Guidance for Cancer Diagnosis and Treatment During Pregnancy
As the incidence of cancer among reproductive-age people continues to increase in the United States—with approximately one out of every 1,000 pregnancies complicated by cancer—the Society for Maternal-Fetal Medicine (SMFM) has issued its first evidence-based clinical guidance for diagnosing and...
Studies Suggest Prostate Cancer Screening May Be Equivalent to Breast Cancer Screening in Key Outcomes
A new analysis suggests that prostate cancer screening may compare favorably with screening for breast cancer in terms of identifying significant cancers, reducing mortality, and avoiding unnecessary harms, according to findings presented at the 2026 Annual Congress of the European Association of...
Timely Scans May Reduce Mortality in Patients Who Present to the ER With Hematuria
One in 10 patients who present to the emergency department with visible hematuria may die within 3 months, new research from the United Kingdom has indicated. The WASHOUT study, presented at the European Association of Urology Congress (EAU26) in London, found that a scan administered within 48...
Activity Observed With Novel KRAS Inhibitor in Pancreatic Cancer
A novel KRAS G12D inhibitor produced disease control in almost 80% of patients with heavily pretreated advanced or metastatic KRAS G12D–mutated pancreatic cancer in an early-phase study reported at the 2026 ASCO Gastrointestinal Cancers Symposium. Of 41 evaluable patients treated with single-agent...
p53 Reactivator Rezatapopt in TP53 Y220C–Mutated Solid Tumors
In a phase I trial (PYNNACLE) reported in The New England Journal of Medicine, Dumbrava et al described the toxicity and preliminary activity of rezatapopt in TP53 Y220C–mutated solid tumors. The agent is an investigational, first-in-class, oral, selective p53 reactivator that specifically binds to ...
BCMA CAR T-Cell Therapy in Newly Diagnosed Multiple Myeloma
In a Chinese phase II study (CAREMM-001) reported in the Journal of Clinical Oncology, Yan et al found that B-cell maturation antigen (BCMA) chimeric antigen receptor (CAR) T-cell therapy was highly active in patients with newly diagnosed multiple myeloma who were ineligible for or did not proceed...
Structured Exercise Plan for Patients With Cancer May Reduce Cognitive Effects of Chemotherapy
A structured exercise program in patients with cancer receiving chemotherapy led to a reduction in self-reported cognitive impairment vs those receiving chemotherapy who were not on an exercise plan, according to findings from a nationwide, randomized phase III trial published in JNCCN—Journal of...
Clinical Trials May Misrepresent True Thromboembolic Risks From Cancer Drugs
Researchers have identified that the reporting of venous and arterial thrombotic events in cancer clinical trials is inconsistent and potentially inaccurate, according to a comments article published in the Journal of Clinical Oncology.1 “Mandatory and uniform reporting of all [venous and arterial...
Activity Observed with Novel KRAS Inhibitor in Pancreatic Cancer
A novel KRAS G12D inhibitor produced disease control in almost 80% of patients with heavily pretreated advanced or metastatic KRAS G12D–mutated pancreatic cancer in an early-phase study reported at the 2026 ASCO Gastrointestinal (GI) Cancers Symposium.1 Of 41 evaluable patients treated with...
Combined Tests Could Avoid Unnecessary Cystectomy, Study Finds
Combining a visual inspection of the bladder—systematic endoscopic evaluation—with a blood test to check for the presence of circulating tumor DNA (ctDNA) may accurately predict which patients with bladder cancer still have cancer in their bladder after treatment and which do not. These findings,...
Advanced RCC: After Immunotherapy, Belzutifan Plus Lenvatinib or Cabozantinib?
At the 2026 ASCO Genitourinary Cancers Symposium, Robert J. Motzer, MD, of Memorial Sloan Kettering Cancer Center, presented results from the second interim analysis of the phase III LITESPARK-011 trial showing improved progression-free survival, higher objective response rate, and a trend toward...
I Used AI to Supplement My Oncology Care—It Reshaped My Treatment Plan
A year ago, I was confronting a series of symptoms—including rapid weight loss, abdominal distress, fatigue, and heart issues—that I couldn’t explain. I was just 60 years old and had been in good health, but now I sensed that something was seriously wrong. I made appointments with my primary care...
Can a New Testing Method Allow More Patients With Bladder Cancer to Avoid Radical Cystectomy?
Researchers have reported findings that may help redefine treatment for patients with muscle-invasive bladder cancer, a potentially aggressive form of the disease that is traditionally treated with surgical removal of the bladder. The study, published by Matthew D. Galsky, MD, and colleagues in the ...
High Response Rates With Front-Line Pivekimab Sunirine in BPDCN
Treatment with the novel CD123-targeting antibody-drug conjugate pivekimab sunirine led to a high rate of complete and durable responses in patients with blastic plasmacytoid dendritic cell neoplasm (BPDCN), especially among patients being treated in the front-line setting. The antibody-drug...
Cardiovascular Effects and Risk Factors Identified With BRAF and MEK Inhibition in Melanoma
In a prospective, longitudinal cohort study published in JACC: CardioOncology by Glen et al, cancer therapy–related cardiac dysfunction and hypertension were found to be common cardiovascular adverse events among patients with melanoma who received BRAF or MEK inhibitor therapy. Nearly half of...
ASH Guidelines on Management of Newly Diagnosed and Relapsed/Refractory ALL in AYA Patients
The American Society of Hematology (ASH) released guidelines on front-line management of acute lymphoblastic leukemia (ALL) in adolescents and young adults (AYAs), as well as the management of relapsed or refractory disease in this population. Both guidelines, grounded in evidence-based practice,...
ASH Publishes Clinical Guidelines on AL Amyloidosis Diagnosis
The American Society of Hematology (ASH) has released clinical practice guidelines on the diagnosis of light chain (AL) amyloidosis, which were published in Blood Advances. Additionally, the expert panel behind the guidelines also published a scoping review about the clinical features of systemic...
Early Findings From First Human Study of In Vivo CAR T in Myeloma
The first-in-human clinical trial of an in vivo CAR T-cell therapy for multiple myeloma has shown encouraging clinical outcomes at an early time point, with a safety profile and ease of administration that indicates the off-the-shelf KLN-1010 could be easily deployable, researchers from Australia...
